Validation of KELIM as a Predictive/Prognostic Factor for Maintenance Treatment With iPARP in First-Line Ovarian Cancer

NCT06660147 · clinicaltrials.gov ↗
RECRUITING
Status
327
Enrollment
OTHER
Sponsor class

Conditions

Sponsor

ARCAGY/ GINECO GROUP